2 weeks Ago By ABMN Staff
Thrivent Financial for Lutherans cut its stake in shares of Ascendis Pharma A/S ( NASDAQ:ASND – Free Report ) by 54.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 35,941 shares of the biotechnology company’s stock after selling 42,532 shares during the period.
Thrivent Financial for Lutherans’ holdings in Ascendis Pharma A/S were worth $4,948,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also recently bought and sold shares of ASND. Legato Capital Management LLC lifted its position in shares of Ascendis Pharma A/S by 7.
5% during the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 134 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in Ascendis Pharma A/S by 394.
0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after buying an additional 197 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Ascendis Pharma A/S in the 3rd quarter worth $30,000.
GAMMA Investing LLC boosted its position in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the last quarter.
Finally, Blue Trust Inc. grew its stake in shares of Ascendis Pharma A/S by 415.2% during the fourth quarter.
Blue Trust Inc. now owns 407 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 328 shares in the last quarter. Ascendis Pharma A/S Stock Up 1.
2 % Shares of NASDAQ:ASND opened at $167.99 on Tuesday. The company’s 50-day moving average price is $142.
05 and its 200 day moving average price is $136.15. The company has a market cap of $10.
20 billion, a PE ratio of -23.66 and a beta of 0.62.
Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $169.37.
Wall Street Analyst Weigh In Several research firms recently commented on ASND. JPMorgan Chase & Co. boosted their price target on Ascendis Pharma A/S from $168.
00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 18th. Evercore ISI upped their target price on Ascendis Pharma A/S from $220.
00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, February 18th. Morgan Stanley set a $180.
00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Cantor Fitzgerald upped their price target on shares of Ascendis Pharma A/S from $170.00 to $200.
00 and gave the company an “overweight” rating in a report on Tuesday, February 25th. Finally, UBS Group started coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.
00 target price on the stock. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $204.
64. Read Our Latest Stock Analysis on Ascendis Pharma A/S About Ascendis Pharma A/S ( Free Report ) Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Featured Articles Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S ( NASDAQ:ASND – Free Report ).
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter ..
